OncLive TV

John M. Burke, MD, discusses findings from the phase 3 POLARIX trial in patients with newly diagnosed diffuse large B-cell lymphoma.

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Benjamin Heyman, MD, discusses future therapeutic directions in mantle cell lymphoma.

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Noa Biran, MD, discusses the results of an arm of the ongoing phase 1b/2 STOMP trial evaluating selinexor, dosed at 40 or 60 mg, in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Noelle V. Frey, MD, MSCE, discusses the results of a study evaluating the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia that were presented at the 2021 ASH Annual Meeting & Exposition.

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Matthew S. McKinney, MD, cellular therapy specialist, hematologic oncologist, hematologist (malignant), Duke Health, discusses emerging therapeutic strategies in mantle cell lymphoma (MCL).

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Benjamin Heyman, MD, discusses agents targeting ROR1 in patients with relapsed/refractory mantle cell lymphoma. 

Peter Schmid, MD, PhD, FRCP, discusses additional results from the phase 3 KEYNOTE-522 trial in early-stage triple-negative breast cancer.

Sara A. Hurvitz, MD, discusses the results of subgroup analyses from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.

Georges Azzi, MD, discusses the utility of the Signatera circulating tumor DNA assay as a preferred test in colorectal cancer (CRC).

Evan J. Lipson, MD, discusses the role of circulating tumor DNA ​testing in melanoma.

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies. 

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

Carey K. Anders, MD, discusses leveraging antibody-drug conjugates in the treatment of patients with metastatic triple-negative breast cancer.

Kevin Kalinsky, MD, MS, discusses updated results from the phase 3 RxPONDER trial in patients with hormone receptor-positive, HER2-negative breast cancer.

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in ​metastatic urothelial cancer.

Neal D. Shore, MD, FACS, discusses the rationale for the open-label, randomized phase 2 ENACT trial in prostate cancer. 

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.